Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Acceptability of New Paediatric Vigabatrin in Infants
NCT02220114Completed
- Sponsor
- ORPHELIA Pharma
- Start
- May 2014
- Primary completion
- Dec 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of vigabatrin in infantile epileptic spasms syndrome (IESS) and partial epilepsy, sponsored by ORPHELIA Pharma. Primary endpoint: Individual adherence to the new Soluble Tablets (ST) formulation of Vigabatrin using Medication Event Monitoring System at 12 weeks. Started May 2014; status: completed.
02
Drugs
vigabatrin
03
Conditions
infantile epileptic spasms syndrome (IESS)partial epilepsy
Beyond the preview
Go deeper on NCT02220114.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02220114.